Abstract
Etelcalcetide binds to the extracellular domain of the calcium-sensing receptor (CaSR), while cinacalcet binds to the 7-transmembrane domain of the CaSR; however, it is unknown, whether etelcalcetide has similar effects to cinacalcet on parathyroid hormone (PTH) secretion. The PTH-calcium setpoint and maximum and minimum PTH secretion were determined using an 'in vivo setpoint analyses.' The PTH-calcium setpoint was obtained in a mouse model of primary hyperparathyroidism (PC) and wild-type (WT) mice, with PC mice divided into two groups. The setpoint was obtained after 7days of etelcalcetide (3.0mg/kg BW/day) or vehicle administration via anosmotic pump. After 7days of crossover administration, the setpoint was obtained again. Parathyroid glands were obtained after crossover administration, and CaSR expression was analyzed by immunohistochemistry. Etelcalcetide administration significantly decreased the setpoint from 9.03 ± 0.56mg/dL to 6.80 ± 0.28mg/dL, which was restored to 8.81 ± 0.38mg/dL after vehicle administration. In the second group of mice, vehicle administration did not alter the setpoint (8.84 ± 0.69mg/dL to 8.98 ± 0.63mg/dL), but subsequent etelcalcetide administration significantly decreased it to 7.10 ± 0.72mg/dL. There was no significant change in maximum and minimum PTH secretion. Expression levels of parathyroid CaSR were lower in PC mice than in WT mice; however, no significant differences were observed between the two mouse groups. Etelcalcetide decreased the PTH-calcium setpoint without changing maximum and minimum PTH secretion in PC mice, suggesting that like cinacalcet, etelcalcetide has calcimimetic potency.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have